Saturday, 31 October 2026European Markets

FBD HOLDINGS PLC And VOSS VEKSEL OGLAND Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(VIANEWS) - FBD HOLDINGS PLC (EG7.IR) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
FBD HOLDINGS PLC (EG7.IR) €13.50 7.17% 14.31%
VOSS VEKSEL OGLAND (VVL.OL) kr230.00 4.26% 8.24%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. FBD HOLDINGS PLC (EG7.IR)

7.17% Forward Dividend Yield and 14.31% Return On Equity

FBD Holdings plc, through its subsidiaries, engages in the underwriting of general insurance to farmers, private individuals, and business owners in Ireland. The company operates in two segments, Underwriting and Financial Services. It offers car, home, travel, life and pension, business, and farm insurance products, as well as insurance related to motor, fire, liability, and other damage to property. The company also provides investment, pension and life brokerage, and employee services. It serves customers through a network of 34 branches. FBD Holdings plc was founded in 1969 and is headquartered in Dublin, Ireland.

Earnings Per Share

As for profitability, FBD HOLDINGS PLC has a trailing twelve months EPS of €0.12.

PE Ratio

FBD HOLDINGS PLC has a trailing twelve months price to earnings ratio of 112.5. Meaning, the purchaser of the share is investing €112.5 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.31%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FBD HOLDINGS PLC's stock is considered to be overbought (>=80).

More news about FBD HOLDINGS PLC.

2. VOSS VEKSEL OGLAND (VVL.OL)

4.26% Forward Dividend Yield and 8.24% Return On Equity

Voss Veksel- og Landmandsbank ASA provides banking products and services to private individuals and companies in Norway. The company offers saving accounts; car and other vehicle, home, small, and construction loans; overdrafts facilities; leasing services; bank guarantees; bank and payment cards; insurance products; and online and mobile banking services. The company was founded in 1843 and is based in Voss, Norway.

Earnings Per Share

As for profitability, VOSS VEKSEL OGLAND has a trailing twelve months EPS of kr14.98.

PE Ratio

VOSS VEKSEL OGLAND has a trailing twelve months price to earnings ratio of 15.35. Meaning, the purchaser of the share is investing kr15.35 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.24%.

More news about VOSS VEKSEL OGLAND.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com